Neevashini Chengebroyen1*
Anmol Seelan2
Kamal Yoonus Thajudeen3
Saad Ali Alshehri3
Aritra Biswas4
Israrahmed Adur5
Vino Sundararajan6*
Sajitha Lulu Sudhakaran6
Harpreet Singh7*- 1Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Selangor, Malaysia
- 2Department of Biological Sciences, Sunandan Divatia School of Science, Narsee Monjee Institute of Management Studies (NMIMS), Mumbai, India
- 3Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia
- 4Department of Biotechnology, UNESCO Regional Centre for Biotechnology, Government of India, Faridabad, Haryana, India
- 5Manipal Institute of Regenerative Medicine (MIRM), Manipal Academy of Higher Education (MAHE), Bangalore, Karnataka, India
- 6Integrative Multiomics Lab, School of Bio-Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India
- 7School of Pharmaceutical Sciences (Faculty of Pharmacy), IFTM University, Moradabad, Uttar Pradesh, India
A Correction on
Harnessing nanotechnology for stem-cell therapies: revolutionizing neurodegenerative disorder treatments – a state-of-the-art update
by Chengebroyen N, Seelan A, Yoonus Thajudeen K, Alshehri SA, Biswas A, Adur I, Sundararajan V, Lulu Sudhakaran S and Singh H (2025). Front. Pharmacol. 16:1630475. doi: 10.3389/fphar.2025.1630475
In the published article, there was an error. A correction has been made to the Acknowledgments. This previously stated:
“The authors would like to humbly acknowledge the management of Monash University (Malaysia Campus) and Jeffrey Cheah School of Medicine and Health Sciences (JCSMHS), supporting her overall academic and research pursuits. Authors would like to gratefully acknowledge Sagnik Nag, from JCSMHS MUM, for his continued intellectual support and motivation. The authors extend their appreciation to the Deanship of Research and Graduate Studies at King Khalid University for funding this work through Large Research Project under grant number RGP2/316/46.”
The corrected statement appears below:
“The authors extend their appreciation to the Deanship of Research and Graduate Studies at King Khalid University for funding this work through Large Research Project under grant number RGP2/316/46.”
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: nanomaterial-conjugated regenerative therapy, neurodegenerative disorders, nanomedicine, scaffold, neuroprotective-nanotechnology stem-cell therapy, nanotechnology
Citation: Chengebroyen N, Seelan A, Thajudeen KY, Alshehri SA, Biswas A, Adur I, Sundararajan V, Sudhakaran SL and Singh H (2025) Correction: Harnessing nanotechnology for stem-cell therapies: revolutionizing neurodegenerative disorder treatments – a state-of-the-art update. Front. Pharmacol. 16:1674993. doi: 10.3389/fphar.2025.1674993
Received: 28 July 2025; Accepted: 30 July 2025;
Published: 07 August 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Chengebroyen, Seelan, Thajudeen, Alshehri, Biswas, Adur, Sundararajan, Sudhakaran and Singh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Neevashini Chengebroyen, bmVldmFzaGluaS5jaGVuZ2Vicm95ZW5AbW9uYXNoLmVkdQ==; Harpreet Singh, aGFycHJlZXRwcm9jdG9yQHJlZGlmZm1haWwuY29t; Vino Sundararajan, c3Zpbm9Adml0LmFjLmlu